Mirae Asset Global Investments Co. Ltd. Purchases 9,144 Shares of Merck & Co., Inc. (NYSE:MRK)

Mirae Asset International Investments Co. Ltd. lifted its place in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.8% throughout the first quarter, in accordance with the corporate in its most up-to-date submitting with the Securities and Alternate Fee. The institutional investor owned 1,215,107 shares of the corporate’s inventory after shopping for an extra 9,144 shares throughout the interval. Mirae Asset International Investments Co. Ltd.’s holdings in Merck & Co., Inc. have been value $152,249,000 as of its most up-to-date SEC submitting.

Different hedge funds additionally not too long ago purchased and offered shares of the corporate. Kennedy Capital Administration LLC elevated its holdings in shares of Merck & Co., Inc. by 16.7% within the third quarter. Kennedy Capital Administration LLC now owns 12,573 shares of the corporate’s inventory value $1,294,000 after shopping for an extra 1,795 shares throughout the interval. iA International Asset Administration Inc. grew its place in Merck & Co., Inc. by 28.2% throughout the third quarter. iA International Asset Administration Inc. now owns 121,695 shares of the corporate’s inventory value $12,529,000 after buying an extra 26,800 shares over the last quarter. WealthPlan Funding Administration LLC elevated its stake in Merck & Co., Inc. by 3,477.6% within the third quarter. WealthPlan Funding Administration LLC now owns 10,232 shares of the corporate’s inventory value $1,053,000 after buying an extra 9,946 shares throughout the interval. Ramirez Asset Administration Inc. purchased a brand new stake in Merck & Co., Inc. within the third quarter valued at roughly $1,829,000. Lastly, Townsquare Capital LLC boosted its stake in shares of Merck & Co., Inc. by 0.6% throughout the third quarter. Townsquare Capital LLC now owns 386,796 shares of the corporate’s inventory valued at $39,821,000 after buying an extra 2,394 shares throughout the interval. Institutional buyers personal 76.07% of the corporate’s inventory.

Analyst Rankings Adjustments

MRK has been the subject of quite a lot of analyst studies. Cantor Fitzgerald restated an “chubby” score and issued a $155.00 value goal on shares of Merck & Co., Inc. in a analysis report on Tuesday, June 18th. Wells Fargo & Firm boosted their goal value on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the corporate an “equal weight” score in a report on Wednesday, March twenty seventh. Berenberg Financial institution raised their value goal on Merck & Co., Inc. from $140.00 to $143.00 and gave the corporate a “purchase” score in a analysis report on Monday, April eighth. Societe Generale lowered shares of Merck & Co., Inc. from a “maintain” score to a “promote” score and set a $104.00 value goal for the corporate. in a analysis be aware on Monday, March eleventh. Lastly, Truist Monetary upped their value goal on Merck & Co., Inc. from $142.00 to $143.00 and gave the corporate a “purchase” score in a report on Friday, April twenty sixth. One analyst has rated the inventory with a promote score, three have assigned a maintain score, eight have assigned a purchase score and two have issued a robust purchase score to the corporate. Primarily based on information from MarketBeat.com, the corporate presently has a consensus score of “Average Purchase” and a consensus goal value of $133.00.

Get Our Newest Inventory Report on Merck & Co., Inc.

Merck & Co., Inc. Inventory Up 0.5 %

MRK opened at $126.45 on Friday. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year excessive of $134.63. The agency’s 50 day easy transferring common is $129.14 and its two-hundred day easy transferring common is $124.99. The corporate has a present ratio of 1.25, a fast ratio of 0.99 and a debt-to-equity ratio of 0.77. The corporate has a market capitalization of $320.27 billion, a PE ratio of 140.50, a PEG ratio of two.44 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) final launched its earnings outcomes on Thursday, April twenty fifth. The corporate reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.13. The corporate had income of $15.78 billion for the quarter, in comparison with the consensus estimate of $15.21 billion. Merck & Co., Inc. had a return on fairness of 14.05% and a web margin of three.76%. Merck & Co., Inc.’s quarterly income was up 8.9% in comparison with the identical quarter final 12 months. Throughout the identical interval within the earlier 12 months, the enterprise earned $1.40 earnings per share. As a gaggle, equities analysts forecast that Merck & Co., Inc. will submit 8.62 EPS for the present 12 months.

Merck & Co., Inc. Proclaims Dividend

The enterprise additionally not too long ago disclosed a quarterly dividend, which will likely be paid on Monday, July eighth. Buyers of document on Monday, June seventeenth will likely be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Monday, June seventeenth. This represents a $3.08 dividend on an annualized foundation and a dividend yield of two.44%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare firm worldwide. It operates by two segments, Pharmaceutical and Animal Well being. The Pharmaceutical section provides human well being pharmaceutical merchandise within the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes underneath the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia manufacturers, in addition to vaccine merchandise consisting of preventive pediatric, adolescent, and grownup vaccines underneath the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Stay Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Additionally

Obtain Information & Rankings for Merck & Co. Inc. Day by day – Enter your e mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Merck & Co. Inc. and associated firms with MarketBeat.com’s FREE day by day e mail e-newsletter.